A prospective phase II study of 2-methoxyestradiol administered in combination with bevacizumab in patients with metastatic carcinoid tumors. - Wikidata - awgldk - TriplyDB

A prospective phase II study of 2-methoxyestradiol administered in combination with bevacizumab in patients with metastatic carcinoid tumors.

A prospective phase II study of 2-methoxyestradiol administered in combination with bevacizumab in patients with metastatic carcinoid tumors.

http://www.wikidata.org/entity/Q37640526

about

Management of gastric polyps: an endoscopy-based approach Involvement of reactive oxygen species in 2-methoxyestradiol-induced apoptosis in human neuroblastoma cells Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors.Anti-angiogenic treatment strategies for the therapy of endometriosis.Proteomic signatures associated with p53 mutational status in lung adenocarcinoma.Investigational cancer drugs targeting cell metabolism in clinical development.Endometriosis: alternative methods of medical treatment.Pharmacologic effects of 2-methoxyestradiol on angiotensin type 1 receptor down-regulation in rat liver epithelial and aortic smooth muscle cells DNA strand breaks induced by nuclear hijacking of neuronal NOS as an anti-cancer effect of 2-methoxyestradiol Inclusion complexes of 2-methoxyestradiol with dimethylated and permethylated β-cyclodextrins: models for cyclodextrin-steroid interaction.2-Methoxyestradiol inhibits experimental autoimmune encephalomyelitis through suppression of immune cell activation Pazopanib and depot octreotide in advanced, well-differentiated neuroendocrine tumours: a multicentre, single-group, phase 2 study.Update on management of midgut neuroendocrine tumors.Inhibition of hypoxia inducible factor-1α attenuates abdominal aortic aneurysm progression through the down-regulation of matrix metalloproteinases.Nanoparticles containing insoluble drug for cancer therapy.Gastroenteropancreatic neuroendocrine tumors: new insights in the diagnosis and therapy.Angiogenesis in neuroendocrine tumors: therapeutic applications.Relevance of angiogenesis in neuroendocrine tumors.Vascular endothelial growth factor (VEGF) pathway and neuroendocrine neoplasms (NENs): prognostic and therapeutic considerations.Systemic Therapies for Advanced Pancreatic Neuroendocrine Tumors.Predictive Markers of Response to Everolimus and Sunitinib in Neuroendocrine Tumors.The estrogen metabolites 2-methoxyestradiol and 2-hydroxyestradiol inhibit endometriotic cell proliferation in estrogen-receptor-independent manner.Neuronal Nitric Oxide Synthase-Mediated Genotoxicity of 2-Methoxyestradiol in Hippocampal HT22 Cell Line.2-methoxyestradiol impacts on amino acids-mediated metabolic reprogramming in osteosarcoma cells by its interaction with NMDA receptor.Neuronal nitric oxide synthase induction in the antitumorigenic and neurotoxic effects of 2-methoxyestradiol.Clinical and Preclinical Advances in Gastroenteropancreatic Neuroendocrine Tumor Therapy.2-Methoxyestradiol Affects Mitochondrial Biogenesis Pathway and Succinate Dehydrogenase Complex Flavoprotein Subunit A in Osteosarcoma Cancer Cells.

P2860

Q26864650-FD93A5F0-BA1C-4751-B17A-C8B5A2193D11 Q28394171-C8A4B1DA-B558-467B-9EA2-74226972769B Q33402226-B2C14CFD-FD58-432B-B42C-BE3640C6A37D Q34283036-1539DD1B-51E6-4199-9FF8-DF949D4BD33C Q35492010-A00BAF88-60FB-4DAF-9EBB-225051E9D3A8 Q35615701-6F6F6E30-0148-4767-8402-C9B8EF52A111 Q35668144-D0D59D58-1D03-4C58-B87E-39CE518095B2 Q35878038-0EB1F293-C24C-4CA6-ABD5-6586039AB79D Q36021044-931A97B2-4B12-43A7-9495-34AFD840BD8F Q36389760-1171F7D9-83AC-4615-A717-CA9D9DCDB394 Q36485290-3F4A73AE-20B0-4D97-8C06-A3A47274253D Q36708349-AA20DF08-7316-4F16-A280-B7BF603093BF Q37025143-43D70C87-79D2-4503-AF25-2960446B79ED Q37057231-528335AF-76C9-421D-AAF5-7626D5F009AA Q37693046-8FF72E03-A073-44E1-A09B-3B60167709A2 Q37962416-E9A438A3-D991-43DB-9F90-A2E27C47A833 Q38005887-2E54D3CA-36E5-4FAA-B0DF-BAC368A34131 Q38010658-65613509-88B3-4DBC-B519-AB3CE1431788 Q38250467-BBD68115-1428-401C-AA37-492AF1DE875A Q38650864-52221215-1982-47D3-9DF2-95AF6A069527 Q38716228-5F5DFBAE-6051-4E29-B0DC-004B2D244E1D Q38800424-6EE77B00-171D-4D33-BE95-581C0A4FDB65 Q38834630-201A4D43-AA7C-4733-8B3C-917EBC388BC2 Q38927564-E0DA38DA-E890-413E-B7F4-6EDBBF3529C7 Q38961781-612EAB7C-9F3C-4F9A-9387-19277F8895B4 Q47128709-95EC8A85-D538-4E2E-A914-C32A7B9C8B75 Q47257443-544C19CC-CC43-4E1C-8499-1531880266D2

P2860

A prospective phase II study of 2-methoxyestradiol administered in combination with bevacizumab in patients with metastatic carcinoid tumors.

http://www.wikidata.org/entity/Q37640526

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 20 October 2010

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

A prospective phase II study o ...... h metastatic carcinoid tumors.

@en

A prospective phase II study o ...... h metastatic carcinoid tumors.

@nl

type

label

A prospective phase II study o ...... h metastatic carcinoid tumors.

@en

A prospective phase II study o ...... h metastatic carcinoid tumors.

@nl

prefLabel

A prospective phase II study o ...... h metastatic carcinoid tumors.

@en

A prospective phase II study o ...... h metastatic carcinoid tumors.

@nl

P1433

Q37640526-94CFC6F7-9F1D-4276-8291-92CB580DCD23

P1476

Q37640526-06FB79B2-AC91-4723-A7D4-1B51D19A1A93

P2093

Q37640526-41D3887F-18EF-4863-9C6E-9D82B05A9331

Q37640526-4BB119C4-3488-4C0E-9CF2-D2BCE97358C5

Q37640526-6048FA9D-EE92-45DB-86DA-AC7ECCC84DF8

Q37640526-6DE9F277-0B19-4FDC-9EBC-A6B403D02DE0

Q37640526-D447BE84-2D68-4409-BE7F-C966E9BD65A2

Q37640526-F35826E6-8933-4473-B7DA-1AC0F47C1E7B

Q37640526-F6A6C3E4-599A-4AA3-B797-97084DBA4E42

P2860

Q37640526-0C9A092B-48F3-4D4D-BCA9-4C541F8A5EB9

Q37640526-1578C9E0-AEBA-40A6-BB3C-0095F6616274

Q37640526-1C6F7D44-70C5-40CC-95A0-9C9ED70148CE

Q37640526-1C8DAAA9-BE9C-4168-8C69-C26C4E901FEC

Q37640526-1F59A3FA-C551-4255-8A77-702990761B59

Q37640526-3C7EB455-E57E-439E-9B61-BB2764DA91A9

Q37640526-52713049-3598-4B6B-979C-B80B08321651

Q37640526-5A03F722-C31C-4DD4-9A74-CC9E67AD10A8

Q37640526-7912375B-0F36-4E4C-B035-A5A2A413CA6D

Q37640526-9CC338F1-BF29-4A4B-A69D-D6F4C7E481E3

P2888

Q37640526-B95447CD-4A4E-4CDC-9C62-B5ACFD73BEE7

P304

Q37640526-97750D27-951A-4508-A312-FFB1FB8DB4B1

P31

Q37640526-85559997-532F-49C6-A283-EC50F4477FDF

P356

Q37640526-37E19366-0448-48E1-9B0F-3C4E22FD858F

P433

Q37640526-D52487CE-8E5A-4DBD-B60F-63ECC98D7334

P478

Q37640526-12D6979E-2685-462E-B40C-CB87AA673202

P50

Q37640526-5D245BE0-A96E-4AA7-8AA0-BE3542FBCB7A

Q37640526-5FB494FB-0123-48BE-A70F-7029F8E3940B

P577

Q37640526-32944C65-D84C-4A50-BEAD-1D958492F003

P698

Q37640526-B78B2B58-8BFC-42EC-ADFA-358EA56DE9DB

P921

Q37640526-5D97F1C8-2F49-423C-AD3A-9D0724BF3D17

Q37640526-F49FC924-E238-4371-B266-78921DCBCC35

P932

Q37640526-88E1B387-ECFF-47EC-B47E-DE9E8C4E27FD

P356

S00280-010-1478-7

P1433

Cancer Chemotherapy and Pharmacology

P1476

A prospective phase II study o ...... h metastatic carcinoid tumors.

@en

P2093

Andrew X Zhu

http://www.w3.org/2001/XMLSchema#string

Carolyn Sidor

http://www.w3.org/2001/XMLSchema#string

Eileen Regan

http://www.w3.org/2001/XMLSchema#string

Jennifer A Chan

http://www.w3.org/2001/XMLSchema#string

Lawrence S Blaszkowsky

http://www.w3.org/2001/XMLSchema#string

Matthew H Kulke

http://www.w3.org/2001/XMLSchema#string

Thomas A Abrams

http://www.w3.org/2001/XMLSchema#string

P2860

Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors.

Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors.

O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors.

2-methoxyestradiol inhibits hypoxia-inducible factor-1{alpha} and suppresses growth of lesions in a mouse model of endometriosis.

A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas

Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma.

Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study

Combination targeted therapy in advanced renal cell carcinoma.

Activity of sunitinib in patients with advanced neuroendocrine tumors.

Elevated expression of vascular endothelial growth factor correlates with increased angiogenesis and decreased progression-free survival among patients with low-grade neuroendocrine tumors.

P2888

s00280-010-1478-7

P304

293-300

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00280-010-1478-7

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

68

http://www.w3.org/2001/XMLSchema#string

P50

Charles S. Fuchs

Jeffrey A Meyerhardt

P577

2010-10-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20960192

http://www.w3.org/2001/XMLSchema#string

P921

2-methoxyestradiol

P932

3955980

http://www.w3.org/2001/XMLSchema#string